NCT07001436View on ClinicalTrials.gov

A Pharmacokinetics and Safety Study of Azvudine Tablets in Subjects With Mild-To-Moderate GFR Decline in Renal Insufficiency and in Healthy Subjects

PHASE1RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 20, 2025

Primary Completion Date

August 30, 2025

Study Completion Date

September 30, 2025

Conditions
Renal Insufficiency
Interventions
DRUG

Azvudine tablets

On the first day of the study, a single oral dose of 3 mg ( 3 tablets ) of Azvudine tablets is taken orally on an empty stomach.

Trial Locations (1)

Unknown

RECRUITING

Beijing Jishuitan Hospital, Beijing

All Listed Sponsors
lead

Henan Genuine Biotech Co., Ltd.

INDUSTRY